JP2021513972A5 - - Google Patents
Info
- Publication number
- JP2021513972A5 JP2021513972A5 JP2020543492A JP2020543492A JP2021513972A5 JP 2021513972 A5 JP2021513972 A5 JP 2021513972A5 JP 2020543492 A JP2020543492 A JP 2020543492A JP 2020543492 A JP2020543492 A JP 2020543492A JP 2021513972 A5 JP2021513972 A5 JP 2021513972A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- tic
- speech
- social
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023198772A JP2024023383A (ja) | 2018-02-16 | 2023-11-24 | 社会的機能障害の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862761253P | 2018-02-16 | 2018-02-16 | |
| US62/761,253 | 2018-02-16 | ||
| PCT/US2019/018263 WO2019161236A1 (en) | 2018-02-16 | 2019-02-15 | Methods of treating social function disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198772A Division JP2024023383A (ja) | 2018-02-16 | 2023-11-24 | 社会的機能障害の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513972A JP2021513972A (ja) | 2021-06-03 |
| JP2021513972A5 true JP2021513972A5 (https=) | 2022-02-15 |
Family
ID=65529920
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543492A Pending JP2021513972A (ja) | 2018-02-16 | 2019-02-15 | 社会的機能障害の治療方法 |
| JP2023198772A Pending JP2024023383A (ja) | 2018-02-16 | 2023-11-24 | 社会的機能障害の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198772A Pending JP2024023383A (ja) | 2018-02-16 | 2023-11-24 | 社会的機能障害の治療方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (3) | US20210008030A1 (https=) |
| JP (2) | JP2021513972A (https=) |
| WO (1) | WO2019161236A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201510665WA (en) | 2009-12-04 | 2016-01-28 | Sunovion Pharmaceuticals Inc | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
| MA45795A (fr) | 2016-07-29 | 2019-06-05 | Sunovion Pharmaceuticals Inc | Composés et compositions, et utilisations associées |
| MX390141B (es) | 2017-02-16 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Metodos para tratar esquizofrenia |
| CA3070993C (en) | 2017-08-02 | 2025-05-20 | Sunovion Pharmaceuticals Inc. | ISOCHROMANE COMPOUNDS AND THEIR USES |
| UA130249C2 (uk) | 2018-02-16 | 2025-12-31 | Сумітомо Фарма Америка, Інк. | Солі, кристалічні форми і способи їх отримання |
| US20200179336A1 (en) * | 2018-12-06 | 2020-06-11 | Sunovion Pharmaceuticals Inc. | Methods of treating neurological and psychiatric disorders |
| CA3180115A1 (en) | 2020-04-14 | 2021-10-21 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders |
| AU2022348905A1 (en) | 2021-09-23 | 2024-04-11 | Sumitomo Pharma America, Inc. | Methods of treating metabolic disorders |
| TW202600129A (zh) * | 2024-02-23 | 2026-01-01 | 美商住友製藥美國公司 | 烏洛托隆（ulotaront）鹽酸鹽的製造方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| SG10201510665WA (en) | 2009-12-04 | 2016-01-28 | Sunovion Pharmaceuticals Inc | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
| MX390141B (es) * | 2017-02-16 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Metodos para tratar esquizofrenia |
-
2019
- 2019-02-15 JP JP2020543492A patent/JP2021513972A/ja active Pending
- 2019-02-15 WO PCT/US2019/018263 patent/WO2019161236A1/en not_active Ceased
- 2019-02-15 US US16/970,089 patent/US20210008030A1/en not_active Abandoned
-
2023
- 2023-03-29 US US18/192,234 patent/US20240050401A1/en not_active Abandoned
- 2023-11-24 JP JP2023198772A patent/JP2024023383A/ja active Pending
-
2024
- 2024-12-19 US US18/987,706 patent/US20250302800A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513972A5 (https=) | ||
| JP2006526031A5 (https=) | ||
| JP2007530694A5 (https=) | ||
| JP2024516371A5 (https=) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2020097577A5 (https=) | ||
| TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
| JP2010077141A5 (https=) | ||
| JP2004526788A5 (https=) | ||
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| JP2006143751A5 (https=) | ||
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| CN113784963A (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
| JP2015502974A5 (https=) | ||
| JP2011527332A5 (https=) | ||
| JP2011527333A5 (https=) | ||
| EP2639229A3 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| JP2020507589A5 (https=) | ||
| JP2012506872A5 (https=) | ||
| JP2019151627A5 (https=) | ||
| JP2007510741A5 (https=) | ||
| JP2021530488A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| JP2009532434A5 (https=) | ||
| JP2010513489A5 (https=) |